Research Interests:
The study of the Pharmacokinetic/pharmacodynamic relationships of various drugs. Various phases of antiviral drug development (HIV, HCV, HBV).

Selected Publications:
Moore SM, Cannon JS, Tanhehco YC, Hamzeh FM, Ambinder RF (2001) Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother 45:2082-91

Jackson JB, Barnett S, Piwowar-Manning E, Apuzzo L, Raines C, Hendrix C, Hamzeh F, Gallant J. (2003) A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk. AIDS 17:547-53

Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, Ruan P, Wu H, Lee J, Flexner C; AIDS Clinical Trials Group 365 Study Team (2003) Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin Pharmacol Ther 73:159-69

Krauss, Miller, and Fayez M. Hamzeh (2004) Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol Scand. 109:374-7.

Holland DT, DiFrancesco R, Stone J, Hamzeh F, Connor JD, Morse GD; Adult and Pediatric AIDS Clinical Trials Group Pharmacology Laboratory Committees, Pediatric AIDS Clinical Trials Group. (2004) Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother 48:824-31

Miller AD, Krauss GL, Hamzeh FM (2004) Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol Scand 109:374-7

Ginsburg AS, Lee J, Woolwine SC, Grosset JH, Hamzeh FM, Bishai WR. (2005) Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system. Antimicrob Agents Chemother 49:853-6